Brieflands

History

The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.

Business Profile

Brieflands is a Registered Trademark with record number 1454012.
Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
- KvK number: 89235444.
- BTW (VAT) number: NL864918896B01 (check online at VIES )
- RSIN: 864918896
Nedmedica is our related company which is specialized in Author Services.
Our former branding name was Kowsarmedical Publishing (2010-2021).

Communities in Brieflands

Select a community to browse its collections.

Recent Submissions

Assessment of HCV-RNA Testing Results and Genotype Distribution Among Anti-HCV-Positive Patients in Aksu Prefecture, Xinjiang, China: A Retrospective Hospital-Based Study
(Brieflands, 2026-12-31)
Hangchuan Mei
;
Gang Niu
;
Junsheng Ma
;
Hui Song
Background: Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. However, local data on HCV RNA positivity and genotype distribution among anti-HCV-positive patients in Aksu Prefecture remain limited. Objectives: To describe HCV-RNA positivity and genotype distribution among anti-HCV-positive patients tested at a regional hospital in Aksu Prefecture and to evaluate demographic and geographic associations with HCV-RNA positivity. Methods: This retrospective hospital-based study included 4,735 independent anti-HCV-positive patients with valid HCV-RNA results at the Third People’s Hospital of Aksu Prefecture in 2024. Proportions were reported with Wilson 95% confidence intervals (CIs). A multivariable logistic regression model including sex, age group, and region was fitted to the individual-level analytical subset from eight regions (n = 3,842). Results: HCV RNA was detected in 1,361 of 4,735 anti-HCV-positive patients (28.74%; 95% CI, 27.47% - 30.05%). In the eight-region individual-level subset, 1,283 of 3,842 patients were HCV RNA-positive (33.39%; 95% CI, 31.92% - 34.90%). Male sex was associated with higher adjusted odds of HCV RNA positivity than female sex (adjusted odds ratio [aOR], 2.22; 95% CI, 1.91 - 2.57). Patients aged 31 - 40 years also had higher adjusted odds of HCV RNA positivity than those aged ≥ 61 years (aOR, 1.75; 95% CI, 1.41 - 2.16). Genotype 1b was the most frequent (41.59%), followed by 3a (26.60%), 2a (19.54%), and 3b (11.32%). Conclusions: HCV-RNA positivity and genotype distribution varied across demographic and geographic strata within this hospital-tested, anti-HCV-positive cohort. These estimates do not represent population-level prevalence in Aksu Prefecture.
Lower Serum Kindlin-2 Levels Are Associated with Liver Cirrhosis: A Preliminary Study
(Brieflands, 2026-12-31)
Özgür Altun
;
Olga Metin
;
Yucel Arman
;
Şengul Aydın Yoldemir
;
Okan Dikker
Background: Kindlin-2 is a focal adhesion protein involved in cell-cell and cell-extracellular matrix adhesion. These functions influence cell behavior and processes such as fibrosis. Kindlin-2 has recently been reported to play important roles in fibrotic diseases. Objectives: This study aimed to assess the association between serum kindlin-2 levels and liver cirrhosis. Methods: The study included 48 individuals with liver cirrhosis and 40 healthy controls. Serum kindlin-2 levels were measured using an enzyme-linked immunosorbent assay (ELISA). Complete blood count parameters and liver function tests were assessed. Liver fibrosis was evaluated using noninvasive indices, including the aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 (FIB-4) index. Mortality risk was evaluated using the Model for End-Stage Liver Disease-Sodium (MELD-Na) score. Results: Serum kindlin-2 levels were lower in the liver cirrhosis group (P = 0.014). Kindlin-2 levels were inversely associated with alanine aminotransferase (ALT), aspartate aminotransferase (AST), and aminotransferase-to-platelet ratio index (APRI) scores and positively associated with platelet count. Low kindlin-2 levels were independently associated with liver cirrhosis. Conclusions: Low serum kindlin-2 levels were associated with liver cirrhosis. Correlations were observed between kindlin-2 levels and markers of liver fibrosis, as well as certain liver function tests. These findings may be a consequence of the cirrhosis process.
Development of a Predictive Model for Early Death in Metastatic Hepatocellular Carcinoma Based on the SEER Database
(Brieflands, 2026-12-31)
Weiguo Liu
;
Moli Chen
;
Xue Wei
;
Peng Wang
Background: Hepatocellular carcinoma (HCC) often has an insidious onset and high metastatic potential. Early death, defined as death within 3 months of initial diagnosis, is common in metastatic HCC (mHCC). However, few studies have used current staging systems to predict this outcome. Objectives: This study aimed to develop and internally validate a predictive model for early death in mHCC (American Joint Committee on Cancer [AJCC], 8th edition, M1 stage IVB) using the Surveillance, Epidemiology, and End Results (SEER) database and to construct a nomogram for individual risk estimation. Methods: Data from patients diagnosed with metastatic HCC between 2018 and 2023 were extracted from the SEER database (version 9.0.43.0). A total of 5,877 patients were randomly divided into training (n = 4,114) and validation (n = 1,763) cohorts at a ratio of 7:3. Univariable and multivariable logistic regression analyses were performed to identify predictors. A nomogram was subsequently constructed, and its performance was evaluated using the concordance index (C-index), calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA). Results: The early death rate was 62.5% in the training cohort and 63.4% in the validation cohort. The final multivariable model retained nine predictors: age, tumor size, alpha-fetoprotein (AFP), bone metastasis, brain metastasis, lung metastasis, marital status, radiotherapy, and chemotherapy. The nomogram achieved a C-index of 0.740 in the training cohort and 0.746 in the validation cohort, outperforming the conventional tumor-node-metastasis (TNM) staging system (C-index: 0.531). Calibration curves demonstrated close agreement between predicted and observed outcomes, and decision curve analysis (DCA) indicated net clinical benefit. A reduced model excluding radiotherapy and chemotherapy had a validation C-index of 0.605. Conclusions: This SEER-based nomogram integrates nine readily available clinical variables to predict early death in patients with mHCC and demonstrates robust discrimination, calibration, and clinical utility. It provides an intuitive quantitative tool to identify high-risk patients and guide individualized treatment and follow-up strategies.
Outcome Prediction in Burn Care: A Comparative Study of Machine Learning Algorithms on Structured Clinical Data
(Brieflands, 2026-07-31)
Abdolkhalegh Keshavarzi
;
Ali Sam
;
Nahid Abolpour
;
Zahra Taghados
;
Iliya Keshavarzi
Background: Early prediction of burn outcomes using structured clinical information available during prehospital care, triage, and early admission may support triage, counseling, and resource planning. Objectives: To compare five prespecified classifiers for the early prediction of final outcome, number of surgeries, intensive care unit (ICU) length of stay, and hospital length of stay using routinely collected prehospital and admission registry data. Methods: This retrospective single-center study used burn-registry records from Shiraz Burn Hospital for the period from 20 March 2020 to 20 March 2026. After records with final outcomes of transfer, discharge at the patient's own request, or unknown/not recorded were excluded, the analytic registry contained 4,127 records with 4,127 unique patient identifiers. Final outcome was modeled as recovery versus death. For the targets of number of surgeries and length of stay, deaths were excluded because death is a competing terminal event. Candidate predictors comprised demographic characteristics; referral and triage information; level of consciousness; vital signs and acute clinical findings; burn mechanism, intent, depth, total body surface area (TBSA), and anatomical regions; comorbidities; and prehospital treatment indicators. Target labels were not imputed. Logistic regression, decision tree, random forest, support vector machine (SVM), and k-nearest neighbors were compared using repeated stratified five-fold cross-validation, with macro-F1 as the primary model-selection metric, followed by evaluation on an independent 20% held-out test set. Results: The final outcome was recovery in 3,175 patients (76.9%) and death in 952 (23.1%). Among the 3,175 recovered patients included in the resource-use analyses, surgery categories were 0 surgeries in 48.1%, 1 in 14.0%, 2 in 10.3%, and > 2 in 27.6%; ICU-stay categories were no ICU/0 days in 74.9%, 1 - 7 days in 12.6%, and > 7 days in 12.5%; and hospital-stay categories were ≤ 7 days in 26.4%, 8 - 14 days in 33.2%, and > 14 days in 40.4%. In the development-set comparison, SVM achieved the highest macro-F1 for final outcome (0.895), whereas random forest performed best in predicting the number of surgeries, ICU length of stay, and hospital length of stay, with macro-F1 values of 0.466, 0.618, and 0.575, respectively. On the held-out test set, the selected SVM achieved a macro-F1 of 0.905 and a balanced accuracy of 0.932 for final outcome. For death prediction, sensitivity was 93.7% and positive predictive value was 79.2%. Random forest achieved held-out macro-F1 values of 0.459, 0.699, and 0.575 for number of surgeries, ICU length of stay, and hospital length of stay, respectively. Conclusions: Among the five evaluated classifiers, SVM provided the strongest performance for early prediction of final clinical outcome, whereas random forest performed best for the three resource-use outcomes. Early structured burn-registry variables enabled strong discrimination between recovery and death, including high sensitivity for mortality, whereas prediction of operative burden and hospital length of stay remained more challenging. These findings support further external and prospective validation before clinical implementation.
Association of Empagliflozin Therapy with the Development of Erythrocytosis in Individuals with Type 2 Diabetes and Chronic Kidney Disease
(Brieflands, 2026-10-31)
Samaneh Hashemi
;
Leila Barahimi
;
Mohammad Kogani
;
Tina Eghdampanah Foumani
;
Ehsan Moradi-Joo
Background: Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is widely used in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). In addition to its established cardiorenal benefits, emerging evidence suggests potential effects on hemoglobin levels and erythrocytosis. Objectives: This study aimed to evaluate the association between empagliflozin therapy and erythrocytosis in patients with T2DM and CKD. Methods: This retrospective cohort study included 300 patients with T2DM and CKD treated at two teaching hospitals between 2023 and 2024. Patients were categorized as empagliflozin users (n = 100) or nonusers (n = 200). Erythrocytosis was assessed after ≥ 6 months of continuous therapy. Unadjusted, age- and sex-adjusted, and fully adjusted logistic regression analyses were performed. Results: Erythrocytosis occurred in 8 of 100 users (8%) and 5 of 200 nonusers (2.5%). Empagliflozin use was associated with higher odds of erythrocytosis in the unadjusted model (odds ratio [OR] = 3.64; 95% confidence interval [CI], 0.59 - 22.20; P = 0.161) and the age- and sex-adjusted model (OR = 4.38; 95% CI, 0.66 - 28.90; P = 0.125). In the fully adjusted model, the association remained directionally positive but imprecise (OR = 41.73; 95% CI, 0.11 - 15061.54; P = 0.214). Increasing age was inversely associated with erythrocytosis in the age- and sex-adjusted model (OR = 0.91; 95% CI, 0.84 - 0.97; P = 0.012). Conclusions: Empagliflozin therapy was associated with higher point estimates of the odds of erythrocytosis; however, the lack of statistical significance and wide confidence intervals indicate substantial uncertainty. These findings are exploratory and should be interpreted cautiously. Larger prospective studies are needed to clarify this potential association.